VALGANCICLOVIR HYDROCHLORIDE (valganciclovir) by Hetero is dna polymerase inhibitors [moa]. Approved for cmv retinitis in patients with acquired immunodeficiency syndrome (aids), cmv disease in kidney, heart and 3 more indications. First approved in 2020.
DNA Polymerase Inhibitors
Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor
Worked on VALGANCICLOVIR HYDROCHLORIDE at Hetero? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 in Combination With Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subjects With Hepatocellular Carcinoma
A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma
Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients
Efficacy of Letermovir in Preventing Cytomegalovirus (CMV) Infection in Lung Transplant Recipients vs. Valganciclovir.
De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant Recipients